AstraZeneca opens 570,000-square-foot R&D site in Cambridge, MA

· Health · United States

AstraZeneca inaugurated a 570,000-square-foot research and development building in Cambridge, Massachusetts, part of a roughly $1 billion investment in the Kendall Square hub of US biotechnology. The company says the site will soon employ 2,000 workers. AstraZeneca prides itself on investing roughly a quarter of its annual revenue into R&D, and the new facility underscores its commitment to the Boston-area life sciences cluster even as the sector there has come under pressure. The opening comes after a spate of China-focused dealmaking by large pharma companies, highlighting how Western drugmakers are balancing US-based discovery operations against cheaper pipeline assets licensed from Chinese biotechs. The new site adds to the concentration of large pharmaceutical research operations in the Boston area.

Why it matters：The investment signals continued commitment to the US biotech cluster even as large drugmakers increasingly license pipeline assets from China, a balance that shapes where discovery research and jobs are located.

Key points

  • The building covers 570,000 square feet in Cambridge, Massachusetts.
  • AstraZeneca says it will soon employ 2,000 workers there.
  • The investment in the site is about $1 billion.

Sources (original reporting)

More stories from this day